- Author(s):
- Organization(s):
Mystic Pharmaceuticals
Development of new Form Fill Seal technology offers significant economic and functional benefits to aseptic packaging and delivery of intranasal drug products.
In the case of formulations under development for indications such as pain management, migraine, seizure and biologics such as vaccines, which require a delivery system with precision control over spray plume geometry and deposition to the nasal mucosa for systemic uptake, pharmaceutical manufacturers have turned their attention to unit-dose, aseptic intranasal drug products. This type of delivery system for intranasal drugs presents challenges due to the cost and difficulty of aseptic packaging of the drug and device components. However, a new development in unit-dose aseptic packaging based on a novel Form Fill Seal (FFS) technology is showing great promise as a cost-effective alternative.